Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Impact of Clonal Heterogeneity in Newly Diagnosed, Transplant-Eligible Multiple Myeloma - Subgroup Analysis of the GMMG HD6 Phase III Trial

Blood (2024) 144 (Supplement 1): 84.

https://doi.org/10.1182/blood-2024-201972

Published: 2024

Journal Articles

Quality of Life in the Multicenter, Randomized, Phase 3 GMMG-HD6 Trial Applying Elotuzumab, Lenalidomide, Bortezomib and Dexaemethason in Patients with Newly-Diagnosed Multiple Myeloma

Blood (2024) 144 (Supplement 1): 1963.

https://doi.org/10.1182/blood-2024-205230

Published: 2024

Journal Articles

Salvage Autologous Transplant and Lenalidomide Maintenance Versus Continuous Lenalidomide/Dexamethasone for Relapsed Multiple Myeloma: Long Term Follow up Results of the Randomized GMMG Phase III Multicenter Trial Relapse

Blood (2023) 142 (Supplement 1): 782.

https://doi.org/10.1182/blood-2023-178835

Published: 2023

Journal Articles

Immunological Subgroups Predicting Efficacy of Elotuzumab in Multiple Myeloma Patients: Insights from the GMMG-HD6 Clinical Trial

Blood (2023) 142 (Supplement 1): 1991.

https://doi.org/10.1182/blood-2023-189169

Published: 2023

Journal Articles

Prediction of Early Death and Severe Infections during Novel Agent-Based Induction Therapy in Newly-Diagnosed Multiple Myeloma: An Intergroup Analysis from the German Speaking Myeloma Multicenter Group, the Dutch-Belgian Cooperative Trial Group for Hematology Oncology Foundation and the European Myeloma Network

Blood (2021) 138 (Supplement 1): 3792.

https://doi.org/10.1182/blood-2021-145289

Published: 2021

Journal Articles

Elotuzumab in Combination with Lenalidomide, Bortezomib, Dexamethasone and Autologous Transplantation for Newly-Diagnosed Multiple Myeloma: Results from the Randomized Phase III GMMG-HD6 Trial

Blood (2021) 138 (Supplement 1): 486.

https://doi.org/10.1182/blood-2021-147323

Published: 2021

Journal Articles

A randomized phase 3 trial of autologous vs allogeneic transplantation as part of first-line therapy in poor-risk peripheral T-NHL

Blood (2021) 137 (19): 2646–2656.

https://doi.org/10.1182/blood.2020008825

Published: 2021

Includes: Supplemental data

Journal Articles

Salvage Autologous Transplant and Lenalidomide Maintenance Versus Continuous Lenalidomide/Dexamethasone for Relapsed Multiple Myeloma: Results of the Randomized GMMG Phase III Multicenter Trial Relapse

Blood (2018) 132 (Supplement 1): 253.

https://doi.org/10.1182/blood-2018-99-111203

Published: 2018

Journal Articles

Subgroup Analyses of the Randomized GMMG Phase III Multicenter Trial Relapse Suggest Survival Benefit of Salvage Autologous Transplant Primarily in Low Risk Multiple Myeloma

Blood (2018) 132 (Supplement 1): 254.

https://doi.org/10.1182/blood-2018-99-119762

Published: 2018

Journal Articles

Phase I/II Study on Cytarabine and Idarubicin Combined with Escalating Doses of Clofarabine in Untreated Patients with Acute Myeloid Leukemia and High Risk for Induction Failure (AMLSG 17-10 CIARA)

Blood (2016) 128 (22): 4038.

https://doi.org/10.1182/blood.V128.22.4038.4038

Published: 2016

Journal Articles

Impact of Age and Midostaurin-Dose on Response and Outcome in Acute Myeloid Leukemia with FLT3 -ITD: Interim-Analyses of the AMLSG 16-10 Trial

Richard F. Schlenk, MD, Walter Fiedler, MD, Helmut R. Salih, MD, Gerald Wulf, MD, Felicitas Thol, MD, Andrea Kündgen, MD, Thomas Kindler, MD, Hans-Juergen Salwender, MD, Michael Lübbert, MD, Peter Brossart, MD, Jörg Westermann, MD Prof, Doris Kraemer, MD, Katharina Goetze, MD, Heinz-August Horst, MD PhD, Jürgen Krauter, MD, Michael Girschikofsky, MD, Mark Ringhoffer, MD, Thomas Südhoff, MD, Gerhard Held, MD, Hartmut H. Kirchner, MD, Wolff Schmiegel, MD, Richard Greil, MD, Martin Griesshammer, MD, Elisabeth Lange, MD, Uwe Martens, MD, Bernd Hertenstein, MD, Maike de Wit, Elisabeth Koller, MD, Andreas L. Petzer, MD, Tanja Hesse, MD, Volker Runde, MD, Peter Reimer, MD, Beate S. Schultheis, MD, Heinz Kirchen, MD, Frank Griesinger, MD, Holger Hebart, MD, Gerhard Heil, Stephan Kremers, David Nachbaur, MD, Nadezda Basara, MD, Carsten Schwänen, Daniel Schöndube, MD, Jochen Greiner, Anja Münnich, Daniela Weber, Verena I. Gaidzik, MD, Maria-Veronica Teleanu, MD, Peter Paschka, MD, Frauke Theis, Axel Benner, Michael Heuser, MD, Konstanze Döhner, MD, Arnold Ganser, MD, Hartmut Döhner, MD

Blood (2016) 128 (22): 449.

https://doi.org/10.1182/blood.V128.22.449.449

Published: 2016

Journal Articles

Different Outcome for Angioimmunoblastic T-Cell Lymphoma (AIL) and Peripheral T-Cell Lymphoma Unspecified (PTCL-U) Following Upfront Autologous Stem Cell Transplantation.

Peter Reimer, MD, Thomas Ruediger, MD, Florian Weissinger, MD, Hans Konrad Mueller-Hermelink, Andreas Engert, Hermann Einsele, Martin Wilhelm

Blood (2006) 108 (11): 5431.

https://doi.org/10.1182/blood.V108.11.5431.5431

Published: 2006

Journal Articles

Autologous Stem Cell Transplantation as First-Line Therapy in Peripheral T-Cell Lymphomas. A Prospective Multicenter Study.

Peter Reimer, MD, Thomas Ruediger, MD, Tobias Schertlin, MD, Eva Geissinger, MD, Florian Weissinger, MD, Hermann Einsele, Hans Konrad Mueller-Hermelink, Martin Wilhelm

Blood (2005) 106 (11): 2074.

https://doi.org/10.1182/blood.V106.11.2074.2074

Published: 2005

Journal Articles

Expression of Leukemia-Associated Antigens (LAA) in Patients with Acute Myelogenous Leukemia (AML).

Bjoern Schoettker, MD, Peter Reimer, MD, Volker Kunzmann, MD, Hermann Einsele, MD, Florian Weissinger, MD

Blood (2005) 106 (11): 4497.

https://doi.org/10.1182/blood.V106.11.4497.4497

Published: 2005

Journal Articles

Autologous Stem Cell Transplantation as First Line Therapy in Peripheral T Cell Lymphomas. Update of a Prospective Multicenter Study.

Peter Reimer, MD, Thomas Ruediger, MD, Tobias Schertlin, Eva Geissinger, MD, Florian Weissinger, MD, Hans Konrad Mueller-Hermelink, Martin Wilhelm

Blood (2004) 104 (11): 904.

https://doi.org/10.1182/blood.V104.11.904.904

Published: 2004

Journal Articles

Nodular lymphocyte-predominant Hodgkin lymphoma with nodules resembling T-cell/histiocyte-rich B-cell lymphoma: differential diagnosis between nodular lymphocyte-predominant Hodgkin lymphoma and T-cell/histiocyte-rich B-cell lymphoma

Ludmila Boudová, Emina Torlakovic, Jan Delabie, Peter Reimer, Beate Pfistner, Sabine Wiedenmann, Volker Diehl, Hans-Konrad Müller-Hermelink, Thomas Rüdiger

Blood (2003) 102 (10): 3753–3758.

https://doi.org/10.1182/blood-2003-02-0626

Published: 2003

Journal Articles

γδ T cells for immune therapy of patients with lymphoid malignancies

Martin Wilhelm, Volker Kunzmann, Susanne Eckstein, Peter Reimer, Florian Weissinger, Thomas Ruediger, Hans-Peter Tony

Blood (2003) 102 (1): 200–206.

https://doi.org/10.1182/blood-2002-12-3665

Published: 2003

NARROW

Impact of Clonal Heterogeneity in Newly Diagnosed, Transplant-Eligible Multiple Myeloma - Subgroup Analysis of the GMMG HD6 Phase III Trial

Quality of Life in the Multicenter, Randomized, Phase 3 GMMG-HD6 Trial Applying Elotuzumab, Lenalidomide, Bortezomib and Dexaemethason in Patients with Newly-Diagnosed Multiple Myeloma

Salvage Autologous Transplant and Lenalidomide Maintenance Versus Continuous Lenalidomide/Dexamethasone for Relapsed Multiple Myeloma: Long Term Follow up Results of the Randomized GMMG Phase III Multicenter Trial Relapse

Immunological Subgroups Predicting Efficacy of Elotuzumab in Multiple Myeloma Patients: Insights from the GMMG-HD6 Clinical Trial

Elotuzumab in Combination with Lenalidomide, Bortezomib, Dexamethasone and Autologous Transplantation for Newly-Diagnosed Multiple Myeloma: Results from the Randomized Phase III GMMG-HD6 Trial

A randomized phase 3 trial of autologous vs allogeneic transplantation as part of first-line therapy in poor-risk peripheral T-NHL

Salvage Autologous Transplant and Lenalidomide Maintenance Versus Continuous Lenalidomide/Dexamethasone for Relapsed Multiple Myeloma: Results of the Randomized GMMG Phase III Multicenter Trial Relapse

Subgroup Analyses of the Randomized GMMG Phase III Multicenter Trial Relapse Suggest Survival Benefit of Salvage Autologous Transplant Primarily in Low Risk Multiple Myeloma

Phase I/II Study on Cytarabine and Idarubicin Combined with Escalating Doses of Clofarabine in Untreated Patients with Acute Myeloid Leukemia and High Risk for Induction Failure (AMLSG 17-10 CIARA)

Impact of Age and Midostaurin-Dose on Response and Outcome in Acute Myeloid Leukemia with FLT3 -ITD: Interim-Analyses of the AMLSG 16-10 Trial

Different Outcome for Angioimmunoblastic T-Cell Lymphoma (AIL) and Peripheral T-Cell Lymphoma Unspecified (PTCL-U) Following Upfront Autologous Stem Cell Transplantation.

Autologous Stem Cell Transplantation as First-Line Therapy in Peripheral T-Cell Lymphomas. A Prospective Multicenter Study.

Expression of Leukemia-Associated Antigens (LAA) in Patients with Acute Myelogenous Leukemia (AML).

Autologous Stem Cell Transplantation as First Line Therapy in Peripheral T Cell Lymphomas. Update of a Prospective Multicenter Study.

Nodular lymphocyte-predominant Hodgkin lymphoma with nodules resembling T-cell/histiocyte-rich B-cell lymphoma: differential diagnosis between nodular lymphocyte-predominant Hodgkin lymphoma and T-cell/histiocyte-rich B-cell lymphoma

γδ T cells for immune therapy of patients with lymphoid malignancies

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only